Treatment of chronic axial back pain with 60-day percutaneous medial branch PNS: Primary end point results from a prospective, multicenter study
| Autor: | Kasra Amirdelfan, Warren Grace, Mehul J. Desai, Timothy R. Deer, Meredith J McGee, Joseph W. Boggs, Puneet Sayal, Thomas J. Hopkins, Abram H. Burgher, Christopher A. Gilmore, Michael J. DePalma, Steven P. Cohen, Sean Li |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Percutaneous business.industry medicine.medical_treatment Low back pain Surgery Anesthesiology and Pain Medicine Lumbar Treatment Outcome Multicenter study Back Pain medicine Clinical endpoint Back pain Transcutaneous Electric Nerve Stimulation Humans Prospective Studies medicine.symptom Lead (electronics) business Neurostimulation Low Back Pain |
| Zdroj: | Pain practice : the official journal of World Institute of Pain. 21(8) |
| ISSN: | 1533-2500 |
| Popis: | BACKGROUND The objective of this prospective, multicenter study is to characterize responses to percutaneous medial branch peripheral nerve stimulation (PNS) to determine if results from earlier, smaller single-center studies and reports were generalizable when performed at a larger number and wider variety of centers in patients recalcitrant to nonsurgical treatments. MATERIALS & METHODS Participants with chronic axial low back pain (LBP) were implanted with percutaneous PNS leads targeting the lumbar medial branch nerves for up to 60 days, after which the leads were removed. Participants were followed long-term for 12 months after the 2-month PNS treatment. Data collection is complete for visits through end of treatment with PNS (primary end point) and 6 months after lead removal (8 months after start of treatment), with some participant follow-up visits thereafter in progress. RESULTS Clinically and statistically significant reductions in pain intensity, disability, and pain interference were reported by a majority of participants. Seventy-three percent of participants were successes for the primary end point, reporting clinically significant (≥30%) reductions in back pain intensity after the 2-month percutaneous PNS treatment (n = 54/74). Whereas prospective follow-up is ongoing, among those who had already completed the long-term follow-up visits (n = 51), reductions in pain intensity, disability, and pain interference were sustained in a majority of participants through 14 months after the start of treatment. CONCLUSION Given the minimally invasive, nondestructive nature of percutaneous PNS and the significant benefits experienced by participants who were recalcitrant to nonsurgical treatments, percutaneous PNS may provide a promising first-line neurostimulation treatment option for patients with chronic axial back pain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text